1. A method of controlling the secretions from glands selected from the group consisting of holocrine glands, and the holocrine-like components of cerumen and mammary glands in patients whose level of glandular secretion is greater than is desirable by administering to said patient a secretorily controlling amount of botulinum toxin.

2. The method of claim 1 wherein the holocrine glands are selected from the group consisting of sebaceous glands, pilosebaceous glands, meibomium glands, and glands of Zeiss and Moll.

3. The method of claim 1 wherein the conditions resulting from greater then desirable levels of secretion are selected from the group consisting of seborrheic dermatitis, rhinophyma, seborrheic blepharitis, sebaceous cysts, excess cerumen, unwanted milk production, and bacterial infections of these glands resulting in hidradenitis, furuncles, carbuncles, styes and chalazions.

4. The method of claim 1 wherein the method of administration is topical.

5. The method of claim 1 wherein the method of administration is by injection.

6. The method of claim 5 wherein injection is subdermal.

7. The method of claim 5 wherein injection is transdermal.

8. The method of claim 5 wherein injection is intradermal.

9. The method of claim 5 wherein injection is intramuscular.

10. The method of claim 6 comprising the subdermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

11. The method of claim 10 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

12. The method of claim 7 comprising the transdermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

13. The method of claim 12 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

14. The method of claim 8 comprising the intradermal injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

15. The method of claim 14 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

16. The method of claim 9 comprising the intramuscular injection of botulinum toxin A at multiple sites in the skin, wherein the sites of adjacent injections are separated by about 0.5 to 10 cm.

17. The method of claim 16 wherein the sites of adjacent injections are separated by about 1.5 to about 3 cm.

18. The method of claim 6 wherein the amount injected is between 1 and 10 U of Botulinum Toxin A .

19. The method of claim 18 wherein the amount injected is between 2 and 3 U of Botulinum Toxin A .

20. The method of claim 7 wherein the amount injected is between 1 and 10 U of Botulinum Toxin A.

21. The method of claim 20 wherein the amount injected is between 2 and 3 U of Botulinum Toxin A.

22. The method of claim 8 wherein the amount injected is between 1 and 10 U of Botulinum Toxin A.

23. The method of claim 22 wherein the amount injected is between 2 and 3 U of Botulinum Toxin A.

24. The method of claim 9 wherein the amount injected is between 1 and 10 U of Botulinum Toxin A.

25. The method of claim 24 wherein the amount injected is between 2 and 3 U of Botulinum Toxin A.

26. The method of Claim 1, wherein said method is repeated periodically to inhibit the recurrence of undesirable levels of secretion.

27. The method of Claim 26, wherein said method is repeated at intervals from about 3 months to about 6 months to inhibit said recurrence.

28. The method of Claim 27, wherein said method is repeated at intervals of about 4 months to inhibit said recurrence.

29. The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin B.

30. The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin C.

31. The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin D.

32. The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin E.

33. The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin F.

34. The method of Claim 1, wherein the botulinum toxin comprises botulinum toxin G.

35. The use of botulinum toxin for the preparation of a pharmacologically acceptable composition for controlling the secretions from glands selected from the group consisting of holocrine glands, and the holocrine-like components of cerumen and mammary glands in patients whose level of glandular secretion is greater than is desirable.

36. The use of claim 35 wherein said secretions are those emanating from the holocrine glands selected from the group consisting of sebaceous glands, pilosebaceous glands, meibomium glands, glands of Zeiss and Moll,

37. The use of 35 wherein the conditions resulting from greater then desirable levels of secretion are selected from the group consisting of seborrheic dermatitis, rhinophyma, seborrheic blepharitis, sebaceous cysts, excess cerumen, unwanted milk production, and bacterial infections of these glands resulting in hidradenitis, furuncles, carbuncles, styes and chalazions.

38. The use of claim 35 wherein said composition is intended for topical administration.

39. The use of claim 35 wherein said composition is intended for administration by injection.

40. The use of claim 39 wherein said composition is intended for administration by subdermal injection.

41. The use of claim 39 wherein said composition is intended for administration by transdermal injection.

42. The use of claim 39 wherein said composition is intended for administration by intadermal injection.

43. The use of claim 39 wherein said composition is intended for administration by intramuscular injection

44. A method of smoothing fine wrinkles in the skin and decreasing the skin pore size of a subject in need of same which comprises administering to said patient a pharmacologically effective amount of botulinum toxin.

45. The method of claim 44 wherein the method of administration is topical.

46. The method of claim 44 wherein the method of administration is by injection.

47. The method of claim 46 wherein injection is subdermal.

48. The method of claim 46 wherein injection is transdermal.

49. The method of claim 46 wherein injection is intradermal.

50. The use of botulinum toxin for the preparation of a pharmacologically acceptable composition for smoothing fine wrinkles in the skin and decreasing the skin pore size of a subject in need of.

51. The use of claim 50 wherein said composition is intended for topical administration.

52. The use of claim 50 wherein said composition is intended for administration by injection.

53. The use of claim 52 wherein said composition is intended for administration by subdermal injection.

54. The use of claim 52 wherein said composition is intended for administration by transdermal injection.

55. The use of claim 52 wherein said composition is intended for administration by intadermal injection.